BRMD Aktienübersicht Bristol-Myers Squibb Company erforscht, entwickelt, lizenziert, produziert, vermarktet, vertreibt und verkauft weltweit biopharmazeutische Produkte. Mehr Details
Belohnungen Risikoanalyse Alle Risikoprüfungen anzeigen Erfassen Sie Ihre Gedanken, Links und Unternehmenseinschätzung
Bristol-Myers Squibb Company Wettbewerber Preisentwicklung & Leistung
Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für Bristol-Myers Squibb Historische Aktienkurse Aktueller Aktienkurs US$55.00 52-Wochen-Hoch US$56.52 52-Wochen-Tief US$36.79 Beta 0.45 1 Monat Veränderung -0.69% 3 Monate Veränderung 3.73% 1 Jahr Veränderung n/a 3 Jahre Veränderung n/a 5 Jahre Veränderung n/a Veränderung seit IPO -11.53%
Aktuelle Nachrichten und Updates Bristol Myers Squibb Receives Positive Chmp Opinion for Car T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
Bristol Myers Squibb Presents Results from Checkmate -8Hw Analysis Evaluating Opdivo® (Nivolumab) Plus Yervoy® (Ipilimumab) Compared to Opdivo Monotherap Jan 27
Bristol Myers Squibb Announces FDA Approval of Cobenfy Jan 08
Bristol Myers Squibb Announces U.S. Food and Drug Administration Approves Opdivo Qvantig™? (nivolumab and Hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo®? (Nivolumor Opdivo) Indications Dec 28 Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) Plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer
Bristol-Myers Squibb Company to Report Q4, 2024 Results on Feb 06, 2025 Dec 19 Weitere Updates anzeigen Bristol Myers Squibb Receives Positive Chmp Opinion for Car T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
Bristol Myers Squibb Presents Results from Checkmate -8Hw Analysis Evaluating Opdivo® (Nivolumab) Plus Yervoy® (Ipilimumab) Compared to Opdivo Monotherap Jan 27
Bristol Myers Squibb Announces FDA Approval of Cobenfy Jan 08
Bristol Myers Squibb Announces U.S. Food and Drug Administration Approves Opdivo Qvantig™? (nivolumab and Hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo®? (Nivolumor Opdivo) Indications Dec 28 Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) Plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer
Bristol-Myers Squibb Company to Report Q4, 2024 Results on Feb 06, 2025 Dec 19
Bristol Myers Squibb Company Declares Quarterly Dividend, Payable on February 3, 2025 Dec 12
Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio At Ash 2024 with Long-Term Survival Data and Results from Expanding Pipeline Dec 10
Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms Nov 20
Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors Nov 16
Bristol-Myers Squibb Company Showcases the Continued Strength of Its Cardiovascular Portfolio with New Clinical and Real-World Data At American Heart Association Scientific Sessions 2024 Nov 12 Bristol Myers Squibb Presents New Long-Term Data from the EMERGENT Program Evaluating Covenfy in Adults with Schizophrenia At Psych Congress 2024
Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data At Psych Congress 2024 Oct 28
U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC) Oct 04
Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (Deucravacitinib) Efficacy in Both Moderate-To-Severe Scalp Psoriasis and in A Real-World Setting Sep 29
U.S. Food and Drug Administration Approves Bristol Myers Squibb's COBENFY (xanomeline and Trospium Chlorx), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults Sep 27 Bristol Myers Squibb Announces New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis Sep 18
Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from Checkmate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® Plus Yervoy® in Advanced Melanoma Sep 16
Bristol-Myers Squibb Company to Report Q3, 2024 Results on Oct 31, 2024 Sep 12
Bristol Myers Squibb Announces Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS (Mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) Sep 02
Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma Aug 21 European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma Aug 19
Bristol-Myers Squibb Company Announces Intangible Asset Impairment Charges for the Three Months Ended June 30, 2024 Jul 26
Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma Jul 20
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC) Jun 22 Bristol-Myers Squibb Company to Report Q2, 2024 Results on Jul 26, 2024
Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024 Jun 19 Bristol Myers Squibb Declares A Quarterly Dividend, Payable on August 1, 2024 Jun 18
Bristol Myers Squibb Announces Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carinoma in Checkmate -9DW Trial Jun 06 Bristol Myers Squibb’S Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented At 2024 Asco® Annual Meeting
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma Jun 01
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine May 30
Bristol Myers Squibb Announces New Four-Year Results from the POETYK PSO Long-Term Extension Trial of Sotyktu (Deucravacitinib) Treatment in Adult Patients with Moderate-To-Severe Plaque Psoriasis May 18 Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approves by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma May 17
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial May 11
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase) May 08
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer May 07
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma Apr 27
First quarter 2024 earnings released: US$5.89 loss per share (vs US$1.08 profit in 1Q 2023) Apr 26
Bristol Myers Squibb Announces KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC) Apr 10
U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio’S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy Apr 06
European Commission Expands Approval of Bristol Myers Squibb’S Reblozyl® (Luspatercept) Apr 03 Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (Oozanimod) in Patients with Moderate to Severe Active Crohn's Disease
Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Mar 27 Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
Bristol-Myers Squibb Company, Annual General Meeting, May 07, 2024 Mar 20
Bristol-Myers Squibb Company, Annual General Meeting, May 07, 2024 Mar 19 Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Karuna Therapeutics, Inc. (NasdaqGM:KRTX) from Capital International Investors, FMR LLC, The Vanguard Group, Inc., T. Rowe Price Group, Inc. (NasdaqGS:TROW) and others. Mar 18
FDA Advisory Committee Votes in Favor of Bristol-Myers Squibb Company and 2seventy bio, Inc. Abecma for Triple-Class Exposed Multiple Myeloma in Further Lines of Therapy Mar 16
Fourth quarter dividend of US$0.60 announced Mar 15
U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Mar 15
Bristol-Myers Squibb Company to Report Q1, 2024 Results on Apr 25, 2024 Mar 12
U.S. Food and Drug Administration Approves Bristol-Myers Squibb Company's Opdivo Mar 08
Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of RayzeBio, Inc. (NasdaqGM:RYZB). Feb 27 Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of RayzeBio, Inc. (NasdaqGM:RYZB). Feb 26
Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS) Feb 23
Bristol Myers Squibb Announces U.S. Food and Drug Administration (FDA) Accepts for Priority Review the Supplemental New Drug Application (sNDA) for KRAZATI (adagrasib) in Combination with Cetuximab for the Treatment of Patients with Previously Treated KRASG12C-Mutated Locally Advanced or Metastatic Colorectal Cancer Feb 22
Full year 2023 earnings released: EPS: US$3.88 (vs US$2.97 in FY 2022) Feb 17
Bristol-Myers Squibb Company Announces Management Changes Feb 16
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Augtyro (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors Feb 15
Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer Feb 10
Bristol Myers Squibb and 2seventy bio, Inc. Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study Feb 06
Bristol-Myers Squibb Company Announces Three Regulatory Acceptances from the U.S. Food and Drug Administration (FDA) and Japan’S Ministry of Health, Labour and Welfare (MHLW) for Breyanzi Jan 31
Bristol Myers Squibb Announces the First Disclosure of Data from the Phase 3 CheckMate -67T Trial Jan 28
Bristol-Myers Squibb Company Receives Positive Chmp Opinion for Car T Cell Therapy Abecma (Idecabtagene Vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma Jan 26 Bristol Myers Squibb and Exelixis, Inc. Announce Four-Year Follow-Up Results from the CheckMate -9ER Trial Evaluating Opdivo (cabozantinib) Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders. Jan 23
Bristol Myers Squibb Announces Results from the Phase 3 Randomized Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Jan 21 Aktionärsrenditen BRMD GB Pharmaceuticals GB Markt 7D 0% 2.1% 0.3% 1Y n/a 10.1% 12.1%
Vollständige Aktionärsrenditen anzeigen
Rendite im Vergleich zur Industrie: Unzureichende Daten, um festzustellen, wie BRMD im Vergleich zur Branche UK Pharmaceuticals abschneidet.
Rendite vs. Markt: Unzureichende Daten, um festzustellen, wie BRMD im Vergleich zum UK Markt abgeschnitten hat.
Preisvolatilität Is BRMD's price volatile compared to industry and market? BRMD volatility BRMD Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 7.7% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.4% 10% least volatile stocks in GB Market 2.7%
Stabiler Aktienkurs: Der Aktienkurs von BRMD war in den letzten 3 Monaten im Vergleich zum UK -Markt volatil.
Volatilität im Zeitverlauf: Unzureichende Daten , um die Volatilitätsveränderung von BRMD im vergangenen Jahr zu bestimmen.
Über das Unternehmen Gegründet Mitarbeiter CEO Website 1887 34,100 Chris Boerner www.bms.com
Bristol-Myers Squibb Company erforscht, entwickelt, lizenziert, produziert, vermarktet, vertreibt und verkauft weltweit biopharmazeutische Produkte. Das Unternehmen bietet Produkte für die Bereiche Hämatologie, Onkologie, Herz-Kreislauf, Immunologie, Fibrose und neurowissenschaftliche Erkrankungen an. Zu den Produkten des Unternehmens gehören Eliquis zur Verringerung des Risikos eines Schlaganfalls/einer systemischen Embolie bei nicht-valvulärem Vorhofflimmern und zur Behandlung von TVT/PE; Opdivo für verschiedene Krebsindikationen, darunter Blasen-, Blut-, Darmkrebs, Kopf- und Halskrebs, RCC, HCC, Lungenkrebs, Melanom, MPM, Magen- und Speiseröhrenkrebs; Pomalyst/Imnovid zur Behandlung des multiplen Myeloms; Orencia zur Behandlung von aktiver rheumatoider Arthritis und Psoriasis-Arthritis; und Sprycel zur Behandlung von Philadelphia-Chromosom-positiver chronisch-myeloischer Leukämie.
Mehr anzeigen Bristol-Myers Squibb Company's Grundlagenzusammenfassung Wie verhalten sich die Erträge und Einnahmen von Bristol-Myers Squibb im Vergleich zum Marktanteil des Unternehmens? BRMD grundlegende Statistiken Marktanteil €111.64b Gewinn(TTM ) -€8.66b Umsatz(TTM ) €46.76b
2.4x Kurs-Umsatz-Verhältnis
-12.9x Kurs-Gewinn-Verhältnis Erträge & Einnahmen Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM) BRMD Gewinn- und Verlustrechnung (TTM ) Einnahmen US$48.30b Kosten der Einnahmen US$11.95b Bruttogewinn US$36.35b Sonstige Ausgaben US$45.30b Umsatz -US$8.95b
Zuletzt gemeldete Gewinne
Dec 31, 2024
Datum des nächsten Gewinnberichts
Apr 24, 2025
Gewinn per Aktie (EPS) -4.41 Bruttomarge 75.26% Nettogewinnspanne -18.53% Schulden/Eigenkapital-Verhältnis 299.1%
Wie hat sich BRMD auf lange Sicht entwickelt?
Historische Performance und Vergleiche Dividenden
4.4% Aktuelle Dividendenrendite
Unternehmensanalyse und Finanzdaten Status Daten Zuletzt aktualisiert (UTC-Zeit) Unternehmensanalyse 2025/02/08 17:29 Aktienkurs zum Tagesende 2025/01/17 00:00 Gewinne 2024/12/31 Jährliche Einnahmen 2024/12/31
Datenquellen Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC . Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
Paket Daten Zeitrahmen Beispiel US-Quelle * Finanzdaten des Unternehmens 10 Jahre Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz Konsensschätzungen der Analysten +3 Jahre Finanzielle Vorausschau Kursziele der Analysten Marktpreise 30 Jahre Aktienkurse Dividenden, Splits und Aktionen Eigentümerschaft 10 Jahre Top-Aktionäre Insiderhandel Verwaltung 10 Jahre Das Führungsteam Direktorium Wichtige Entwicklungen 10 Jahre Ankündigungen des Unternehmens
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr .
Analysemodell und Schneeflocke Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite . Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube .
Erfahren Sie mehr über das Weltklasse-Team , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github .
Analysten-Quellen Bristol-Myers Squibb Company wird von 44 Analysten beobachtet. 23 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
Analyst Einrichtung David Toung Argus Research Company Ishan Majumdar Baptista Research Charles Butler Barclays
41 weitere Analysten anzeigen 